medigraphic.com

2008, Number 1

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2008; 46 (1)

Type 2N Von Willebrand Disease (Normandy)

Morales-De la Vega A, Reyes-Maldonado E, Martínez-Murillo C, Quintana-González S

Language: Spanish
References: 45
Page: 55-62
PDF size: 153.33 Kb.


ABSTRACT

Introduction: the results of the laboratory test for 2N von Willebrand disease (2N vWD) are indistinguishable from those of light or moderate haemophilia A, until the technique that evaluates the operation of the vWF: FVIII binding is performed.
Objective: to determine the prevalence of type 2N vWD in patients diagnosed with light or moderate haemophilia A and type 1 vWD.
Material and methods: twelve healthy donors and twenty-five patients diagnosed with haemophilia A (a carrier) and five suspected of type 1 vWD were included in the study. The common tests of haemostasis for this condition plus the technique of the relationship of the vWF: FVIII recombinant (F VIIIr) binding was performed.
Results: the laboratory results of the 30 patients were concordant with the previous diagnosis. However, three with a previous diagnosis of haemophilia A demonstrated a rate of relationship of the vWF: F VIIIr binding lower than the reference interval obtained from the healthy donors, which means it corresponds to 2N vWD.
Conclusions: the screening method of 2N vWD employed in this study allowed to identify for first time in Mexico, the first cases of this variant with a prevalence of 10%. In our country, this method will allow to establishing accurate diagnosis of 2N vWD and to providing specific treatments.


REFERENCES

  1. Berntorp E, Ingerslev J, Schulman S. Von Willebrand disease: an update in the Aland islands. Summary of a Nordic Symposium on von Willebrand disease, 24–25 September 1998, Mariehamn, Aland. Haemophilia 1999;5(Suppl. 2):1-6.

  2. Favaloro EJ, Facey D, Grispo L. Laboratory assessment of von Willebrand factor. AJCP 1995;104: 264-271.

  3. Jorieux S, Tuley EA, Gaucher C, Mazurier C, Sadler JE. The mutation Arg(53) → Trp causes von Willebrand disease Normandy by abolishing binding to factor VIII. Studies with recombinant von Willebrand factor. Blood 1992;79:563-567.

  4. Ruggeri ZM. Pathogenesis and classification of von Willebrand disease. Haemostasis 1994;24: 265-275.

  5. Schneppenheim R, Thomas KB, Sutor AH. Von Willebrand disease in childhood. Semin Thromb Hemost 1995;21:261-275.

  6. Triplett DA. Laboratory diagnosis of von Willebrand’s disease. Mayo Clin Proc 1991;66: 832-840.

  7. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987;69:454-459.

  8. Ambriz R, Avilés A, Reyna MP, Ballesteros L, Pizzuto J. Enfermedad de von Willebrand. Informe de 60 casos en 24 familias en México. Rev Med IMSS 1984;22:241.

  9. Sadler JE, Gralnick R. Commentary: a new classification for von Willebrand disease. Blood 1994; 84:676-679.

  10. Ewenstein BM. Von Willebrand disease. Annu Rev Med 1997;48:525-542.

  11. Gralnick HR, Williams SB, McKeown LP, Magruder L, Hansmann K, Vail M, Parker RI. Platelet von Willebrand factor. Mayo Clin Proc 1991; 66:634-640.

  12. Meyer D, Piétu G, Fressinaud E, Girma JP. Von Willebrand factor: structure and function. Mayo Clin Proc 1991;66:516-523.

  13. Ginsburg D. The molecular biology of von Willebrand disease. Haemophilia 1999;5(Suppl. 2):19-27.

  14. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.

  15. Federici AB, Mannucci M. Diagnosis and management of von Willebrand disease. Haemophilia 1999;5(Suppl. 2):28-37.

  16. Goodeve AC. Laboratory methods for the genetic diagnosis of bleeding disorders. Clin Lab Haem 1998;20:3-19.

  17. Ingerslev J, Gürsel T. Diagnosis of von Willebrand disease. Haemophilia 1999;5(Suppl. 2):50-56.

  18. Rick ME. Laboratory diagnosis of von Willebrand’s disease. Clin Lab Med 1994;14:781-794.

  19. Schulman S. Haemostatic and replacement therapy in von Willebrand disease. Haemophilia 1999;5 (Suppl. 2):57-59.

  20. Slaughter TF, Parker JK, Greenberg CS. A rapid method for the diagnosis of von Willebrand’s disease subtypes by the clinical laboratory. Arch Pathol Lab Med 1995;119:148-152.

  21. Mazurier C, Meyer D. Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease –results of an international survey. Thromb Haemost 1996;76: 270-274.

  22. Meyer D, Fressinaud E, Gaucher C, Lavergne JM, Hilbert L, Ribba AS, et al. Gene defects in 150 unrelated french cases with type 2 von Willebrand disease: from the patient to the gene. Thromb Haemost 1997;78:451-456.

  23. Mazurier C, Gaucher C, Jorieux S, Parquet-Gernez A, Goudemand M. Evidence for a von Willebrand factor defect in factor VIII binding in three members of a family previously misdiagnosed mild haemophilia A and carriers: consequences for therapy and genetic counselling. Br J Haematol 1990; 76:372-379.

  24. Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989;74:1591-1599.

  25. Rodgers SE, Lerda NV, Favaloro EJ, Duncan EM, Casey GJ, Quinn DM, et al. Identification of von Willebrand disease type 2N (Normandy) in Australia: a cross-laboratory investigation using different methods. Am J Clin Pathol 2002;118:269-276.

  26. Simon D, Roisenberg I. Type 2N von Willebrand disease mutations in Brazilian individuals. Haemophilia 2004;10:473-476.

  27. Zarnovicanova M, Pelikanova S. Von Willebrand disease-type 2N (case report). Vnitr Lek 2003;49: 319-321.

  28. Casonato A, Pontara E, Zerbinati P, Zucchetto A, Girolami A. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications. Am J Clin Pathol 1998;109:347.

  29. NCCLS Document H21-A2: collection, transport and processing of blood specimens for coagulation testing and performance of coagulations assays. Second Edition, Approved Guideline 11,23:1991.

  30. Procitor R, Rapaport S. The partial thromboplastin with kaolin. Am J Clin Pathol 1961;36:212-219.

  31. Blomback B, Laurent T C. N-terminal and lightscattering studies on fibrinogen and its transformation to fibrin. Arkiv för Kemi 1958;12:137-146.

  32. Destaing F, Duzer A, Ferrand B, Portier A. Dosage du fibrinogéne par la micro-méthode de coagulation de von A Clauss. Pathol Biol (Paris) 1960;8: 1616-1621.

  33. Zacharki LR, Resenstein R. Standardization of the one-stage assay for factor VIII (antihemophilic factor). Am J Clin Pathol 1978;70:280-286.

  34. Bartlett A, Dormandy KM, Hawkey CM, Stableforth P, Voller A. Factor VIII related antigen: measurement by enzyme immunoassay. Br Med J 1976;1:994-996.

  35. Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975;34:306-308.

  36. Caron C, Mazurier C, Goudemand J. Large experience with a factor VIII binding assay of plasma von Willebrand factor using comercial reagents. Br J Haematol 2002;117:716-718.

  37. Batlle J, Blanco-López MJ, Castiñeira MP, López- Fernández MF. Importancia del estudio de la unión del factor VIII al factor de von Willebrand en la hemofilia A. Sangre 1992;37:224.

  38. Schneppenheim R, Budde U, Krey S, Drewke E, Bergmann F, Lechler E, et al. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1. Thromb Haemost 1996;76: 598-602.

  39. Kroner PA, Foster PA, Fahs SA, Montgomery RR. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor. Blood 1996;87:1013-1021.

  40. Schneppenheim R, Lenk H, Obser T, Oldenburg J, Oven F, Schneppenheim S. Recombinant expression of mutations causing von Willebrand disease type Normandy : characterization of a combined defect of factor VIII binding and multimerization. Thromb Haemost 2004;92:36-41.

  41. Mazurier C. Something new about type Normandy von Willebrand disease (type 2N VWD)? Thromb Haemost 2004;92:1-2.

  42. Hilbert L, Jorieux S, Fontenay-Roupe M, Guichetau M, Fressinaud E, Meyer D, et al. Expression of two type 2N von Willebrand disease mutations identified in exon 18 of von Willebrand factor gene. Br J Haematol 2004;127:184-189.

  43. Favaloro EJ, Lillicrap D, Lazzari MA, Cattaneo M, Mazurier C, Woods A, et al. Von Willebrand disease: laboratory aspects of diagnosis and treatment. Haemophilia 2004;10(Suppl 4):164-168.

  44. Hilbert L, D’Oiron R, Fressiinaud E, Meyer D, Mazurier C. First identification and expression of a type 2N von Willebrand disease mutation (E 1078 K) located in exon 25 of von Willebrand factor gene. J Thromb Haemost 2004;2:2271-2273.

  45. Schneppenheim R. The evolving classification of von Willebrand disease. Blood Coagul Fibrinolysis 2005;16(Suppl 1):S3-S10.




2020     |     www.medigraphic.com